

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

NCT07161544

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	AAVantgarde Bio Srl
Enrollment	75 participants

Key Eligibility Criteria

Inclusion (2)

- Molecular diagnosis of Stargardt disease due to ABCA4 mutation
- Willingness to adhere to protocol per informed consent

Exclusion (5)

- Unwillingness to meet the requirements of the study
- Participation in a clinical study with another Investigation Medicinal Product
- Previous participation in another gene or cell therapy trial
- Any condition that would preclude subretinal surgery
- Complicating ocular and/or systemic diseases

Locations (6 total)

Retina Vitreous Associates Medical Group, Los Angeles, California, United States
Mayo Clinic, Rochester, Minnesota, United States
Retina Consultants of Texas, Bellaire, Texas, United States
... and 3 more locations